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Abstract  
Objective  
To investigate the association of single- and multimorbidity with mortality rates in patients with 
schizophrenia compared to the general population. 
Method 
A nationwide cohort study including residents in Denmark between 1995 and 2015. The cohort was 
dichotomously divided by a diagnosis of schizophrenia. Somatic diseases included infections, cancer, 
endocrine, neurologic, cardiovascular, respiratory, digestive, skin, musculoskeletal, and urogenital 
diseases. Hazard ratios (HRs) and population attributable fractions (PAFs) were calculated.  
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Results 
The cohort included 30,210 patients with schizophrenia (mean age(SD)=32.6(11.4), males=57.2%), 
and 5,402,611 from the general population (mean age(SD)=33.0(14.5), males=50.4%). All number of 
somatic diseases were associated with an increased mortality in schizophrenia (HR=16.3 
(95%CI=15.4-17.3) for 1 disease to 21.0 (95%CI=19.1-23.0) for ≥5 diseases), using the general 
population with no somatic disease as reference. Across all somatic diseases, patients with 
schizophrenia showed a HR>2, compared to the general population, and respiratory (PAF=9.3%), 
digestive (PAF=8.2%) and cardiovascular (PAF=7.9%) diseases showed largest contributions to death. 
 
Conclusions  
Patients with schizophrenia showed higher mortality on all levels of multimorbidity, and a doubled 
mortality rate across all somatic diseases, compared to the general population. The findings suggest 
that the clusters and trajectories of symptoms associated with schizophrenia is the main driver of 
the excess mortality. 
 
Keywords 
Physical health 
Physical illness 
Comorbidity  
Mortality  
Clinical aspects   
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Significant outcomes  
 In this nationwide cohort study, we found an increased mortality rate across all levels of somatic 
multimorbidity in patients with schizophrenia, compared to the general population.  
 Different somatic disease systems contribute to the increased mortality in patients with 
schizophrenia, however, the results point towards the signs and symptoms associated with 
schizophrenia as the main driver of the excess mortality.   
Limitations  
 We were not able to adjust for important confounders, such as cigarette smoking, diet habits as 
well as physical activity, as these variables are not available in the Danish registers.  
 Information on the severity of the somatic condition was lacking.  
 
Introduction  
Patients with schizophrenia have a general reduced life expectancy of up to 20 years compared to 
the general population (1). The main causes of death are somatic diseases, such as cardiovascular, 
respiratory and cancer diseases (2). These causes of death are similar to the main causes of death 
observed in the general population, although, the developments within somatic treatments have 
resulted in an improved survival following these and other somatic diseases (3), but data do not 
support similar improved survival following somatic diseases in patients diagnosed with 
schizophrenia (4,5).  
Numerous studies have reported increased mortality following a range of different individual 
somatic diseases in patients with schizophrenia, compared to the general population (6–8). This is 
supported by the established increased risk of somatic morbidity in patients with schizophrenia, 
which is mainly explained by inadequate lifestyle behavior (e.g. excess smoking, poor diet intake, 
and limited physical activity) and adverse effects from antipsychotic treatment (e.g. increased 
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cardiometabolic risk) (9,10). Despite the established increased somatic morbidity in patients with 
schizophrenia (11,12), limited studies have reported outcomes related to somatic multimorbidity (≥2 
diseases in the same individual) in patients with schizophrenia (13,14).  
In the general population, somatic multimorbidity is associated with functional decline, decreased 
quality of life, higher healthcare costs as well as an increased risk of premature mortality, with most 
research on somatic multimorbidity focusing on older people in the general population (15,16). Few 
recent studies have reported an increased risk of somatic multimorbidity in patients with 
schizophrenia (17,18), thus understanding the potential contributing effect of somatic 
multimorbidity to mortality rates in patients diagnosed with schizophrenia is essential. Moreover, 
identifying which somatic disease categories contribute the most to increased mortality rates will 
enable targeted preventive health care strategies.  
 
Aims of the Study 
We examined the association of number of somatic diseases with mortality in patients with 
schizophrenia, as compared to the general population. Secondary, we calculated the population 
attributable fraction (PAF) for all-cause mortality for different disease categories in patients with 
schizophrenia as well as in the general population. Lastly, we compared mortality rates of all specific 
somatic disease categories directly between patients with schizophrenia and the general population.   
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Material and Methods 
Study design  
A nationwide Danish register-based cohort study with follow-up from 1 January 1995 to December 
31 2015. 
 
Data source  
Data were derived from several Danish nationwide registers; 1) the Danish Psychiatric Central 
Research Register (DPCRR) which was established in 1969 and contains information on every 
admission to the psychiatric hospital in Denmark. Valid data are available from 1970, which is the 
year all psychiatric departments at Danish hospitals were obligated to report to the DPCRR. From 
1995, all patients attending psychiatric outpatient services and emergency room were included (19). 
2) the Danish National Patient Register (NPR) which was established in 1977, and initially contained 
somatic hospitalizations, but since 1995; all hospitalizations and outpatient treatments in Denmark 
were also registered (20). 3) The Danish Register of Causes of Death which was established in 1970 
and includes cause and date of deaths among Danish citizens. All deaths are coded in line with the 
rules for World Health Organization (WHO) (21).   
 
Study population 
Residents born in Denmark between 1 January 1930 and 31 December 1997 were included 
(individuals were between 18 and 85 years old in 2015). We identified and created a cohort of all 
patients diagnosed with schizophrenia (ICD-8; 295 or ICD-10; F20) from the initiation of the DPCRR 
to the end of study period. Those who received a schizophrenia diagnosis after 1 January 1995 were 
included from their 18th birthday (thereby contributing to risk time to the general population) until 
time of schizophrenia diagnosis, and then followed until end of study period. The remaining 
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individuals not diagnosed with schizophrenia were considered as the cohort of people from the 
general population. Those who turned 18 years after 1 January 1995 in the general population were 
followed from their 18th birthday until end of follow-up. We included both prevalent and incident 
somatic diseases.   
 
Measure and outcome  
From the NPR, we identified whether individuals from the two cohorts had any somatic 
hospitalizations or outpatient contacts during the follow-up period. Each individual somatic 
diagnostic code were grouped into broader disease categories in accordance with the chapters 
defined by WHO (22). The following chapters were included; infection (ICD-10: A00-B99, ICD-8: 001-
139), cancer (ICD-10: C00-D49, ICD-8: 140-239), endocrine (ICD-10: E00-E89, ICD-8: 240-279), 
neurologic (ICD-10: G00-G99, ICD-8: 320-359), cardiovascular (ICD-10: I00-I99, ICD-8: 390-459), 
respiratory (ICD-10: J00-J99, ICD-8: 460-519), digestive (ICD-10: K00-K95, ICD-8: 520-579), skin (ICD-
10: L00-L99, ICD-8: 680-709), musculoskeletal (ICD-10: M00-M99, ICD-8: 710-739), and urogenital 
(ICD-10: N00-N99, ICD-8: 580-629). The primary study endpoint was time to all-cause mortality. The 
follow-up began on 1 January 1995 or on the cohort member’s 18th birthday, whichever came last. 
The follow-up ended on 31 December 2015, the day of death, or the day of emigration, whichever 
came first. Time of schizophrenia diagnosis (if entry after January 1, 1995) and time of somatic 
hospitalization (if entry after January 1, 1995) were considered as time-dependent covariates during 
follow-up.  
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Explanatory variables     
Demographic covariates included sex, age at study entry and calendar year (1995-1999, 2000-2004, 
2005-2009, 2010-2015) of the index date were included. The total number of somatic diseases 
categories was included and divided into the following groups; 0, 1, 2, 3, 4, or ≥5.  
 
Statistical analysis  
Descriptive analyses were conducted initially to report population characteristics of the two cohorts 
included. Data were reported as mean±SD and n (%) for continuous and categorical variables, 
respectively. Population characteristics were compared between the two cohorts using independent 
sample t-test or chi-square test. 
Second, we utilized a Cox proportional hazards regression model to investigate the individual impact 
of number of somatic diseases on mortality rates in both cohorts, using those from the general 
population with no somatic diseases as the reference, adjusted for age, sex, and calendar period. 
The mortality rates were calculated in a time-dependent manner, so each person could contribute to 
time at risk in each number of disease categories investigated.    
Third, we conducted a Cox proportional hazards regression model to investigate the individual 
impact of somatic disease categories on mortality in both cohorts separately. The HRs were 
estimated as being diagnosed within that specific disease category versus not being diagnosed 
within that specific disease category within their individual cohort. This allowed us to calculate the 
PAF in both cohorts to understand which somatic disease categories affected mortality rates mostly. 
The PAF (expressed as percentage (95%CI)) is a measure of proportion of deaths that might be 
prevented if the exposure (in this case the somatic disease) was not present. We calculated the PAF 
using “punafcc” function in STATA based on the fully adjusted regression model, as previously done 
by others (23).  
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A sensitivity analysis excluding individuals with somatic hospitalization before January 1, 1995 was 
performed to allow only incident patients with somatic diseases.   
All models using Cox proportional hazards regression fulfilled the assumption of linearity. Statistical 
significance was accepted at p-value of <0.05. All statistical analyses were performed with STATA 14 
at the Statistics Denmark server with remote access. 
 
Ethics   
Register-based research in Denmark does not require approval from the Ethics Committee, although, 
all data extracted from the Danish nationwide registers involves personal information, thus 
processing of any personal data were anonymized before analysis. The Danish Data Protection 
Agency (2008-58-0028) approved the use of these data to this current research project.  
 
Results  
Population characteristics  
The cohort included 5,432,821 individuals of which 30,210 (0.6%) had a diagnosis of schizophrenia 
and the remaining 5,402,611 (99.4%) served as controls from the general population, yielding 
415,236 and 79,607,446 person-years, respectively. The mean age (SD) at entry in the schizophrenia 
group was 32.6 (11.4) years and 57.2% were males, whereas the mean age (SD) in the general 
population was 33.0 (14.5) years and 50.4% were males.  
There were fewer individuals who did not develop any somatic disease in patients diagnosed with 
schizophrenia (11.6%) as compared to the general population (33.5%), p<0.001. Patients diagnosed 
with schizophrenia had significant higher levels of one (25.1% vs. 21.7%), two (16.5% vs. 13.3%), 
three (12.6% vs. 9.7%), four (9.1% vs. 6.8%), and more than five (25.1% vs. 15.1%) somatic diseases, 
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compared to the general population (P < 0.001 for all) (Table 1). Total number of deaths were 3658 
(12.1%) among patients with schizophrenia compared to 281,108 (5.2%) deaths in the general 
population, p<0.001. In the cohort of patients diagnosed with schizophrenia, the most frequently 
observed somatic disease categories were the digestive system (38.5%), musculoskeletal system 
(34.5%), and urogenital system (27.3%). In the general population, musculoskeletal (32.5%), 
digestive (22.3%), and urogenital (21.0%) disease categories were most frequent observed. The 
frequency of all somatic disease categories (except cancer) were significantly higher in patients with 
schizophrenia compared to the general population, all p<0.001. Cancer disease had higher frequency 
in the general population as compared to patients with schizophrenia, p<0.001.  
 
Association of number of somatic disease categories with mortality rates  
In patients diagnosed with schizophrenia, the largest relatively increase in mortality was observed 
from no somatic disease (HR: 4.65, 95%CI, 4.20-5.15) to a single somatic disease (HR: 16.34, 95%CI, 
15.41-17.32), and all other number of diseases showed increased mortality compared to the 
corresponding number of disease in the general population. Individuals from the general population 
had a dose response increase in mortality associated with an increasing number of somatic diseases, 
as observed by the relative increased mortality from no somatic disease to a single somatic disease 
(HR: 3.94, 95%CI, 3.89-4.00), and the additional increased mortality rate associated with two somatic 
diseases (HR: 4.81, 95%CI, 4.74-4.88).  
The relative increase in mortality rates from zero to one disease category was 3.51 for patients 
diagnosed with schizophrenia compared to 3.94 for the general population, with corresponding 
number for one to two, two to three, and three to four disease categories being 0.90 vs 1.22, 1.03 vs 
1.18 and 1.19 vs 1.25, respectively.    
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Mortality and population attributable fraction of specific somatic disease systems  
In the cohort of patients with schizophrenia, the somatic disease category with the largest mortality 
rate was respiratory (HR: 1.49, 95%CI, 1.38-1.61), followed by cardiovascular diseases (HR: 1.39, 
95%CI, 1.29-1.51), and cancer diseases (HR: 1.36, 95%CI, 1.25-1.49). However, respiratory diseases 
showed the highest PAF (9.29%, 95%CI, 7.81-10.74), as compared to digestive (8.19%, 95%CI, 5.96-
10.34) and cardiovascular (7.89%, 95%CI, 6.28-9.48) diseases. In the general population, cancer (HR: 
2.02, 95%CI, 2.00-2.04), respiratory (HR: 1.66, 95%CI, 1.65-1.68) and cardiovascular (HR: 1.56, 95%CI, 
1.55-1.57) disease categories showed significant highest all-cause mortality, but PAF estimates 
showed that cancer (17.26%, 95%CI, 17.12-17.40), cardiovascular (14.15%, 95%CI, 13.93-14.36), and 
respiratory diseases (9.08%, 95%CI, 8.95-9.21) had largest impact on the overall mortality.  
 
Comparing mortality rates of each somatic disease between patients with schizophrenia and the 
general population  
In a Cox regression model adjusted for age, gender, calendar year, and number of diseases, the 
highest mortality rates were observed in skin disease (HR: 2.85, 95%CI, 2.64-3.08), musculoskeletal 
disease (HR: 2.85, 95%CI, 2.67-3.04), and digestive disease (HR: 2.79, 95%CI, 2.65-2.94), but across 
all somatic disease categories, patients with schizophrenia had a HR≥2 compared to the general 
population, see table 4. 
 
The sensitivity analysis excluding patients with somatic diseases prior to index to allow only incident 
patients with somatic diseases showed nearly similar results to the primary findings. Cancer disease 
had a larger contribution to mortality in patients with schizophrenia in the sensitivity analysis, as 
compared to the main findings. 
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Discussion 
In this nationwide retrospective cohort study of 5.4 million Danish individuals with a total follow-up 
of 80.0 million person-years, we found that compared to the general population, patients with 
schizophrenia were more likely to have both single as well as somatic multimorbidity. Patients with 
schizophrenia had an increased mortality independent of the number of somatic diseases diagnosed, 
as compared to the general population, with increased mortality differences increasing with somatic 
morbidities, and the largest mortality rate ratio was observed in those not diagnosed with any 
somatic disease between patients with schizophrenia and the general population. Lastly, in an 
analysis adjusted for age, gender, calendar year, and number of disease categories, patients with 
schizophrenia had a more than doubled HR for all individual somatic disease categories. The somatic 
disease categories associated with largest impact on mortality were respiratory, digestive and 
cardiovascular diseases.  
Earlier studies have reported an excess mortality of somatic diseases in patients with 
schizophrenia.(4,5,8,24) Our results indicate that the largest difference in mortality rates between 
patients with schizophrenia and the general population is observed before the development of 
somatic multimorbidity. Laursen et al. (8) previously showed that a Charlson Comorbidity Index 
score of zero was associated to an almost 13-fold increase in mortality rates in patients diagnosed 
with schizophrenia, as compared to people without any contact to a psychiatric hospital, and the 
difference in mortality rates between these populations diminished with increasing comorbidity 
score. Our data showed an initial increase in mortality from zero to one somatic disease in patients 
with schizophrenia, but this mortality rate increase was negated when two, three, four and five 
somatic diseases were added. This finding is consistent with a study by Correll et al. (25) who 
showed that each additional cardiometabolic comorbidity did not significantly increase mortality. 
Once patients with schizophrenia had a single cardiometabolic disease, the addition of another 
comorbid disease did not result in an additive or multiplicative effect on the mortality rates. 
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Together, these findings could indicate a ceiling effect in patients with schizophrenia, particularly in 
prediction of mortality in those who suffer from more than two somatic diseases. The results are 
probably also affected by competing risk, as many patients with schizophrenia die before having the 
chance to develop somatic diseases, and as a consequence the mortality rates will appear higher in 
the lower levels of somatic diseases. For example, the high risk of unnatural deaths in patient with 
schizophrenia might interfere with the results observed. Although, previous studies have suggested 
underdiagnoses and under-treatment of somatic diseases in patients with schizophrenia, as 
compared to the general population (11,26). Our finding, that nearly all somatic disease categories 
(except cancer disease) were more prevalent in patients with schizophrenia, suggests that patients 
with schizophrenia in general do have more somatic disease, and does not directly support previous 
studies that have reported a general lack of somatic disease diagnostics in these patients (18,24). 
However, antipsychotics, antidepressants, and anxiolytics have weight gain properties that 
interferes with the number of patients who develop diseases such as cardiovascular, endocrine, and 
neurologic diseases in patients with schizophrenia. Instead, our results of a doubled mortality risk 
within all somatic disease categories in patients with schizophrenia, adjusted for number of disease 
categories, and demographic variables, could point towards the clusters of signs and symptoms 
associated with schizophrenia as the primary driver of the excess mortality. Several studies have 
reported that patients with SMI receive less medical prophylaxis (27) as well as fewer invasive 
procedures during hospitalization as compared to people without SMI (28). However, a recent 
observational study showed that exposure to secondary preventive cardiovascular treatment was 
associated to a reduced excess mortality in patients with schizophrenia (29). This association is not 
necessarily causal due to the risk of residual confounders, although it suggests that some 
interventions might work to reduce some of the excess mortality in patients with schizophrenia. 
Previous studies have suggested a delayed initiation of somatic treatment in patients with mental 
illnesses as a result of patient-related barriers or a general negative attitudes towards these patients 
by health care professionals (11,30). We believe that patients diagnosed with schizophrenia have a 
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poorer treatment seeking behavior and undergo fewer primary prophylactic treatments at GPs, 
which could even worsen the outcomes on multimorbidity, as compared to the general populations  
Earlier findings have suggested that specific somatic diseases, such as cardiovascular, infection, 
cancer, endocrine, and respiratory, contribute to the excess mortality in patients with schizophrenia 
(24,31). To the best of our knowledge, our study is the first to investigate the contribution of each 
somatic disease category for all-cause mortality and the associated PAF estimates in a nationally 
representative data sample. Since no others have used PAFs in this population, it makes comparison 
difficult, but the use of PAF is highly relevant to understand the proportion of deaths that can be 
prevented if the specific somatic disease category was not present (a theoretical improvement). Our 
results showed that respiratory (9.3%), digestive (8.2%), and cardiovascular (7.9%) diseases had 
largest PAFs in patients with schizophrenia. The sensitivity analysis showed that cancer, 
cardiovascular, and respiratory diseases had largest PAF in patients with schizophrenia. This is 
probably a result of the current data, as it is restricted to individuals born between 1930 and 1997, 
and since cancer appear later in life, not many patients had the chance to develop cancer before 
index. Recent findings from Danish nationwide studies have reported  that cancer, cardiovascular, 
and respiratory causes of death have largest impact on life-years lost in people with schizophrenia 
(32,33). Erlangsen et al. (32) reported that up to 20% of the excess life-years lost in mental disorders 
were related to respiratory diseases. However, the PAFs in patients with schizophrenia were lower 
than the PAFs observed in the general population for these disease categories. Therefore, residual 
confounding needs to be considered to our finding, such as tobacco use as well as substance- or 
alcohol abuse, which is much more prevalent in patients with schizophrenia than in individuals 
without (34), and have shown a large contribution to mortality in patients with schizophrenia (35). 
Lack of healthy diet intake (36), less physical activity (37) as well as a higher impact of unnatural 
deaths in patients with schizophrenia (33) might also skew the results towards a lower contribution 
of somatic diseases in patients with schizophrenia. Together, poor health seeking behavior from 
patients as well as insufficient quality of care provided by caregivers could contribute to the excess 
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mortality observed. There is an urgent need to identify and understand the possible barriers in our 
healthcare system, and future research should aim to focus on interventions and treatment within 
general somatic health, which will enable us to deliver a better-targeted intervention in patients 
with schizophrenia (from a healthcare perspective). The results also suggested that the signs and 
symptoms associated with schizophrenia is the primary driver of the excess mortality, thus, future 
research should focus on general health behavior challenges in patients with schizophrenia to 
identify the barriers that patients are experiencing. 
 
Strengths and limitations  
A major strength in the current study is the nationwide database including inpatient- and outpatient 
somatic diagnoses, which allows the inclusion of less severe cases of somatic disease than studies 
limited to hospitalized cases. However, our study is limited by the lack of data from primary care, 
which would have allowed us more reliable risk estimates than those observed in the current study. 
Our large sample size in combination with the number of events and long follow-up time provide 
strong evidence to understand the impact of different somatic diseases to mortality in patients with 
schizophrenia. However, the large sample size increases the probability to find significance even at 
small differences, thus all results should be interpreted in terms of clinical importance of the 
difference. Important confounders for increased mortality, including cigarette smoking, diet habits 
as well as physical activity, are not available in the Danish registers, thus we were not able to adjust 
for these confounders in the regression models. These confounders are known to have a high impact 
on survival outcomes and is a major concern in patients with schizophrenia due to the limited ability 
to adhere to these healthy lifestyle behaviors. Even though, it is believed that a large fraction of the 
excess somatic morbidity and mortality in patients with schizophrenia is related to their poor 
lifestyle related behavior, it might be difficult to include such variables in the regression models due 
to the relative close association of these variables to the diagnosis of schizophrenia. The differences 
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are believed to be linked specifically to the cluster of signs and symptoms in patients with 
schizophrenia, and as such adjusting for these variables would make results more difficult to apply in 
the general clinical practice. We were not able to assess the severity of the somatic disease, as well 
as we acknowledge that there are variations in outcome within each somatic disease category. 
Previous studies on this topic often report cause of death as the primary outcome, which are limited 
to identify a single cause of death, which does not represent the real-life setting, as people most 
often develop different somatic diseases along their life course up until time of death. Also, the large 
uncertainty associated with death certificates do challenge previous reports (21). Thus, we believe 
the current methodology is a major strength that adds valuable knowledge to the current literature 
regarding this topic.   
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Table 1. Population characteristics. 
 
Characteristics  Schizophrenia General population  P 
Number of subjects, N  30,210 5,402,611  
Number of person-years, y 415,236 79,607,446  
Age at entry, mean (SD), y  32.59 (11.42) 33.03 (14.49) <0.001 
Entry year in calendar periods, n (%)     <0.001 
 1995-1999 23,936 (79.23) 4,258,533 (78.82)  
 2000-2004 1445 (4.78) 409,569 (7.58)  
 2005-2009 2197 (7.27) 404,583 (7.49)  
 2010-2015 2632 (8.71) 329,926 (6.11)  
Gender, n (%)      <0.001 
 Male 17,288 (57.23) 2,725,052 (50.44)  
 Female  12,922 (42.77) 2,677,559 (49.56)  
Number of deaths, n (%)  3658 (12.11) 281,108 (5.20) <0.001 
Number of somatic diseases     
 0 3508 (11.61) 1,811,302 (33.53) <0.001 
 1 7589 (25.12) 1,172,963 (21.71) <0.001 
 2 4994 (16.53) 717,017 (13.27) <0.001 
 3 3794 (12.56) 521,863 (9.66) <0.001 
 4 2758 (9.13) 366,227 (6.78) <0.001 
 ≥5 7567 (25.05) 813,239 (15.05) <0.001 
Somatic disease categories     
 Infection 5185 (17.16) 401,404 (7.43) <0.001 
 Cancer  4457 (14.75) 837,739 (15.51) <0.001 
 Endocrine  5689 (18.83) 491,661 (9.10) <0.001 
 Neurologic  5486 (18.16) 548,004 (10.14) <0.001 
 Cardiovascular  6973 (23.08) 994,839 (18.41) <0.001 
 Respiratory  7973 (26.39) 723,289 (13.39) <0.001 
 Digestive 11,620 (38.46) 1,207,012 (22.34) <0.001 
 Skin  6544 (21.66) 509,584 (9.43) <0.001 
 Musculoskeletal  10,429 (34.52) 1,755,026 (32.48) <0.001 
 Urogenital  8234 (27.26) 1,135,584 (21.02) <0.001 
Data are represented as N (%) for categorical variable and mean (SD) for continuous data. 
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Table 2. Number of somatic diseases and mortality rates in patients with schizophrenia 
compared to the rates in the general population  
 
 
*Adjusted for age, gender, calendar year, and all individual disease systems 
Abbreviations: HR; Hazard Ratio, MRR; Mortality Rate Ratio     
 
 
 
 
 
Table 3. Specific disease systems and mortality rates as well as population attributable 
fraction in patients with schizophrenia and the general population.  
 
 Mortality, HR (95% CI)*  PAF, % of death (95% CI)† 
Disease category  Schizophrenia  General population  Schizophrenia General population 
Infection  1.14 (1.02-1.26) 1.31 (1.29-1.33)  1.53 (0.36-2.68) 1.97 (1.88-2.06) 
Cancer 1.36 (1.25-1.49) 2.02 (2.00-2.04)  4.96 (3.73-6.17) 17.26 (17.12-17.40) 
Endocrine  1.19 (1.09-1.31) 1.46 (1.44-1.48)  2.61 (1.33-3.88) 4.84 (4.73-4.96) 
Neurologic  1.17 (1.07-1.29) 1.31 (1.30-1.32)  2.34 (1.06-3.59) 3.34 (3.23-3.47) 
Cardiovascular  1.39 (1.29-1.51) 1.56 (1.55-1.57)  7.89 (6.28-9.48) 14.15 (13.93-14.36) 
Respiratory  1.49 (1.38-1.61) 1.66 (1.65-1.68)  9.29 (7.81-10.74) 9.08 (8.95-9.21) 
Digestive  1.27 (1.18-1.36) 1.28 (1.27-1.29)  8.19 (5.96-10.34) 7.88 (7.65-8.11) 
Skin 1.26 (1.15-1.38) 1.26 (1.24-1.27)  3.84 (2.52-5.14) 2.23 (2.13-2.34) 
Musculoskeletal  0.90 (0.82-0.98) 0.87 (0.86-0.88)  # # 
Urogenital  0.98 (0.91-1.07) 0.95 (0.94-0.96)  # # 
 
*Calculated separately for each cohort, and adjusted for age, gender, and calendar year  
†Calculated based on the corresponding cox regression model from their respective cohorts  
#Estimates only for diseases with a significant increased effect on mortality 
 
 
  
 Crude mortality, HR (95% CI)  Adjusted mortality, HR (95% CI)*  
Number of 
diseases  
 
Schizophrenia 
 
General population 
  
Schizophrenia 
 
General population 
 
MRR† 
0 4.31 (3.89-4.77) 1.0 (ref.)  4.65 (4.20-5.15) 1.0 (ref.) 4.7 
1 13.60 (12.82-14.42) 4.91 (4.84-4.98)  16.34 (15.41-17.32)  3.94 (3.89-4.00) 4.2 
2 12.77 (11.88-13.73) 6.91 (6.81-7.02)  14.72 (13.69-15.83)  4.81 (4.74-4.88) 3.1 
3 13.74 (12.59-15.01) 9.34 (9.20-9.49)  15.21 (13.39-16.61) 5.65 (5.56-5.74) 2.7 
4 16.53 (14.86-18.39) 12.45 (12.25-12.66)  17.68 (15.90-19.67) 6.66 (6.55-6.77) 2.7 
≥5 21.12 (19.25-23.17) 17.63 (17.34-17.92)  21.00 (19.14-23.04) 8.30 (8.16-8.44) 2.5 
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Table 4. Crude and adjusted mortality rates for individual somatic disease categories in 
schizophrenia versus the general population.   
 
 Schizophrenia vs. General population 
Disease category Crude HR (95% CI) Adjusted HR (95% CI)* Adjusted HR (95% CI)†  
Infection  1.55 (1.41-1.70) 2.38 (2.17-2.62) 2.22 (2.02-2.45) 
Cancer 1.42 (1.32-1.54) 2.19 (2.03-2.36) 2.17 (2.02-2.35) 
Endocrine  1.38 (2.27-1.50) 2.24 (2.06-2.43) 2.16 (1.99-2.34) 
Neurologic  1.54 (1.42-1.67) 2.58 (2.37-2.80) 2.44 (2.25-2.65) 
Cardiovascular  1.53 (1.44-1.63) 2.61 (2.45-2.78) 2.48 (2.33-2.64) 
Respiratory  1.83 (1.72-1.94) 2.91 (2.73-3.09) 2.78 (2.61-2.96) 
Digestive  1.71 (1.62-1.80) 2.99 (2.84-3.16) 2.79 (2.65-2.94) 
Skin 1.94 (1.80-2.10) 3.13 (2.90-3.38) 2.85 (2.64-3.08) 
Musculoskeletal  1.91 (1.79-2.04) 3.39 (3.17-3.61) 2.85 (2.67-3.04) 
Urogenital  1.94 (1.82-2.07) 3.13 (2.94-3.34) 2.77 (2.60-2.95) 
 
*Adjusted for age, gender, and calendar year 
†Adjusted for age, gender, calendar year, and number of disease categories  
 
